Progress in molecular biology and translational science最新文献_第6页

Current progress in CRISPR-Cas systems for cancer. CRISPR-Cas 癌症治疗系统的最新进展。

3区生物学

Progress in molecular biology and translational science Pub Date : 2024-01-01 Epub Date: 2024-08-15 DOI: 10.1016/bs.pmbts.2024.07.007

Hunaiza Fatima, Hajra Ali Raja, Rabia Amir, Alvina Gul, Mustafeez Mujtaba Babar, Jayakumar Rajadas

{"title":"Current progress in CRISPR-Cas systems for cancer.","authors":"Hunaiza Fatima, Hajra Ali Raja, Rabia Amir, Alvina Gul, Mustafeez Mujtaba Babar, Jayakumar Rajadas","doi":"10.1016/bs.pmbts.2024.07.007","DOIUrl":"https://doi.org/10.1016/bs.pmbts.2024.07.007","url":null,"abstract":"Cancer has been a primary contributor to morbidity and mortality worldwide. With an increasing trend of incidence and prevalence of cancer, progress has also been made in its treatment, starting from radiation and chemotherapy to immunotherapy and gene therapy. CRISPR-Cas technique, a promising gene editing tool, has been employed in cancer research for novel treatment regimens, identification of therapeutic targets, and unraveling the genetic mechanisms behind oncogenesis. CRISPR-based genome editing helped in identifying the roles of specific genetic factors linked to treatment resistance, metastasis, and cancer development. CRISPR allows the discovery of genes and treatment options through specifically interrupting tumor activators or activating tumor suppressor genes in cancer cells. Advancements in CRISPR technology, especially the use of immune cells like chimeric antigen receptor (CAR) T cells, has the potential to revolutionize personalized cancer treatment by precisely targeting and killing cancer cells. Furthermore, reactivating tumor suppressor genes makes cancer cells more susceptible to chemotherapy or immunotherapy. CRISPR-mediated genome editing can, hence, help to overcome resistance to traditional cancer treatments. The current manuscript covers that how is the CRISPR technology propelling revolutionary development in the field of cancer research, providing advance perspectives on the molecular causes of the disease and creating new lines for the development of more precise and potent cancer therapies.","PeriodicalId":21157,"journal":{"name":"Progress in molecular biology and translational science","volume":"208 ","pages":"211-229"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142294152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Application of RNA-based therapeutics in glioma: A review. 基于 RNA 的疗法在胶质瘤中的应用：综述。

3区生物学

Progress in molecular biology and translational science Pub Date : 2024-01-01 Epub Date: 2023-12-29 DOI: 10.1016/bs.pmbts.2023.12.001

Mehdi Sanati, Amir R Afshari, Seyed Sajad Ahmadi, Tannaz Jamialahmadi, Amirhossein Sahebkar

引用次数: 0

Drug repurposing: A multi targetted approach to treat cardiac disease from existing classical drugs to modern drug discovery. 药物再利用：从现有经典药物到现代药物发现，治疗心脏病的多靶点方法。

3区生物学

Progress in molecular biology and translational science Pub Date : 2024-01-01 Epub Date: 2024-05-14 DOI: 10.1016/bs.pmbts.2024.02.001

Shyam Tripathi, Kusum Rani, V Samuel Raj, Rashmi K Ambasta

{"title":"Drug repurposing: A multi targetted approach to treat cardiac disease from existing classical drugs to modern drug discovery.","authors":"Shyam Tripathi, Kusum Rani, V Samuel Raj, Rashmi K Ambasta","doi":"10.1016/bs.pmbts.2024.02.001","DOIUrl":"https://doi.org/10.1016/bs.pmbts.2024.02.001","url":null,"abstract":"Cardiovascular diseases (CVDs) are characterized by abnormalities in the heart, blood vessels, and blood flow. CVDs comprise a diverse set of health issues. There are several types of CVDs like stroke, endothelial dysfunction, thrombosis, atherosclerosis, plaque instability and heart failure. Identification of a new drug for heart disease takes longer duration and its safety efficacy test takes even longer duration of research and approval. This chapter explores drug repurposing, nano-therapy, and plant-based treatments for managing CVDs from existing drugs which saves time and safety issues with testing new drugs. Existing drugs like statins, ACE inhibitor, warfarin, beta blockers, aspirin and metformin have been found to be useful in treating cardiac disease. For better drug delivery, nano therapy is opening new avenues for cardiac research by targeting interleukin (IL), TNF and other proteins by proteome interactome analysis. Nanoparticles enable precise delivery to atherosclerotic plaques, inflammation areas, and damaged cardiac tissues. Advancements in nano therapeutic agents, such as drug-eluting stents and drug-loaded nanoparticles are transforming CVDs management. Plant-based treatments, containing phytochemicals from Botanical sources, have potential cardiovascular benefits. These phytochemicals can mitigate risk factors associated with CVDs. The integration of these strategies opens new avenues for personalized, effective, and minimally invasive cardiovascular care. Altogether, traditional drugs, phytochemicals along with nanoparticles can revolutionize the future cardiac health care by identifying their signaling pathway, mechanism and interactome analysis.","PeriodicalId":21157,"journal":{"name":"Progress in molecular biology and translational science","volume":"207 ","pages":"151-192"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141470526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances in CRISPR-Cas systems for epigenetics. 用于表观遗传学的 CRISPR-Cas 系统的进展。

3区生物学

Progress in molecular biology and translational science Pub Date : 2024-01-01 Epub Date: 2024-08-22 DOI: 10.1016/bs.pmbts.2024.07.003

Mahnoor Ilyas, Qasim Shah, Alvina Gul, Huzaifa Ibrahim, Rania Fatima, Mustafeez Mujtaba Babar, Jayakumar Rajadas

{"title":"Advances in CRISPR-Cas systems for epigenetics.","authors":"Mahnoor Ilyas, Qasim Shah, Alvina Gul, Huzaifa Ibrahim, Rania Fatima, Mustafeez Mujtaba Babar, Jayakumar Rajadas","doi":"10.1016/bs.pmbts.2024.07.003","DOIUrl":"https://doi.org/10.1016/bs.pmbts.2024.07.003","url":null,"abstract":"The CRISPR-Cas9 method has revolutionized the gene editing. Epigenetic changes, including DNA methylation, RNA modification, and changes in histone proteins, have been intensively studied and found to play a key role in the pathogenesis of human diseases. CRISPR-While the utility of DNA and chromatin modifications, known as epigenetics, is well understood, the functional significance of various alterations of RNA nucleotides has recently gained attention. Recent advancements in improving CRISPR-based epigenetic modifications has resulted in the availability of a powerful source that can selectively modify DNA, allowing for the maintenance of epigenetic memory over several cell divisions. Accurate identification of DNA methylation at specific locations is crucial for the prompt detection of cancer and other diseases, as DNA methylation is strongly correlated to the onset as well as the advancement of such conditions. Genetic or epigenetic perturbations can disrupt the regulation of imprinted genes, resulting in the development of diseases. When histone code editors and DNA de-/ methyltransferases are coupled with catalytically inactive Cas9 (dCas9), and CRISPRa and CRISPRi, they demonstrate excellent efficacy in editing the epigenome of eukaryotic cells. Advancing and optimizing the extracellular delivery platform can, hence, further facilitate the manipulation of CRISPR-Cas9 gene editing technique in upcoming clinical studies. The current chapter focuses on how the CRISP/ Cas9 system provides an avenue for the epigenetic modifications and its employability for human benefit.","PeriodicalId":21157,"journal":{"name":"Progress in molecular biology and translational science","volume":"208 ","pages":"185-209"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142294133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances in CRISPR-Cas systems for fungal infections. 用于真菌感染的 CRISPR-Cas 系统的进展。

3区生物学

Progress in molecular biology and translational science Pub Date : 2024-01-01 Epub Date: 2024-08-21 DOI: 10.1016/bs.pmbts.2024.07.006

Avinash Singh, Monisa Anwer, Juveriya Israr, Ajay Kumar

{"title":"Advances in CRISPR-Cas systems for fungal infections.","authors":"Avinash Singh, Monisa Anwer, Juveriya Israr, Ajay Kumar","doi":"10.1016/bs.pmbts.2024.07.006","DOIUrl":"https://doi.org/10.1016/bs.pmbts.2024.07.006","url":null,"abstract":"Fungi contain a wide range of bioactive secondary metabolites (SMs) that have numerous applications in various fields, including agriculture, medicine, human health, and more. It is common for genes responsible for the production of secondary metabolites (SMs) to form biosynthetic gene clusters (BGCs). The identification and analysis of numerous unexplored gene clusters (BGCs) and their corresponding substances (SMs) has been significantly facilitated by the recent advancements in genomic and genetic technologies. Nevertheless, the exploration of secondary metabolites with commercial value is impeded by a variety of challenges. The emergence of modern CRISPR/Cas technologies has brought about a paradigm shift in fungal genetic engineering, significantly streamlining the process of discovering new bioactive compounds. This study begins with an examination of fungal biosynthetic gene clusters (BGCs) and their interconnections with the secondary metabolites (SMs) they generate. Following that, a brief summary of the conventional methods employed in fungal genetic engineering is provided. This study explores various sophisticated CRISPR/Cas-based methodologies and their utilization in examining the synthesis of secondary metabolites (SMs) in fungi. The chapter provides an in-depth analysis of the limitations and obstacles encountered in CRISPR/Cas-based systems when applied to fungal genetic engineering. It also proposes promising avenues for future research to optimize the efficiency of these systems.","PeriodicalId":21157,"journal":{"name":"Progress in molecular biology and translational science","volume":"208 ","pages":"83-107"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142294134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Magnetic nanoparticles: An emerging nanomedicine for cancer immunotherapy. 磁性纳米粒子：用于癌症免疫疗法的新兴纳米药物。

3区生物学

Progress in molecular biology and translational science Pub Date : 2024-01-01 Epub Date: 2024-05-31 DOI: 10.1016/bs.pmbts.2024.03.017

Phoomipat Jungcharoen, Jutatip Panaampon, Thanit Imemkamon, Charupong Saengboonmee

引用次数: 0

Biosafety and regulatory issues of RNA therapeutics. RNA 疗法的生物安全和监管问题。

3区生物学

Progress in molecular biology and translational science Pub Date : 2024-01-01 Epub Date: 2024-01-24 DOI: 10.1016/bs.pmbts.2023.12.008

Hue Vu Thi, Lan-Anh Nguyen Thi, Thuy Linh Tang, Dinh-Toi Chu

{"title":"Biosafety and regulatory issues of RNA therapeutics.","authors":"Hue Vu Thi, Lan-Anh Nguyen Thi, Thuy Linh Tang, Dinh-Toi Chu","doi":"10.1016/bs.pmbts.2023.12.008","DOIUrl":"10.1016/bs.pmbts.2023.12.008","url":null,"abstract":"RNA therapy has recently emerged as a therapy targeting specific genes or proteins. With its outstanding advantages, this therapy has opened promising doors for treating and preventing diseases. The great application potential has driven the need for a comprehensive understanding of these therapies, particularly on biosafety and regulatory issues. This chapter began by discussing the risks to RNA therapy, such as off-target effects, immunogenicity and immune responses, and long-term effects. Since then, this therapy's intricate landscape of biosafety issues has been elucidated. Common biosecurity measures applied around the world have also been reviewed. In addition, this chapter emphasized the importance of regulations and laws in applying RNA therapy to prevent and treat human and animal diseases. At the same time, the current legal regulations in the world for RNA therapies have also been thoroughly discussed. To sum up, this chapter has provided a comprehensive perspective on biosafety and regulatory issues for developing RNA therapies. Understanding the biosafety and regulatory issues in RNA therapy can help researchers use this promising new technology safely and effectively in the future.","PeriodicalId":21157,"journal":{"name":"Progress in molecular biology and translational science","volume":"204 ","pages":"311-329"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140065807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

COVID-19 pathogenesis. COVID-19 的发病机制。

3区生物学

Progress in molecular biology and translational science Pub Date : 2024-01-01 Epub Date: 2024-01-05 DOI: 10.1016/bs.pmbts.2023.07.001

Asiya Kamber Zaidi, Rohan Bir Singh, Syed A A Rizvi, Puya Dehgani-Mobaraki, Nicola Palladino

引用次数: 0

Prediction of protein aggregation. 预测蛋白质聚集

3区生物学

Progress in molecular biology and translational science Pub Date : 2024-01-01 Epub Date: 2024-04-16 DOI: 10.1016/bs.pmbts.2024.03.005

Kavyan Khalili, Farnoosh Farzam, Bahareh Dabirmanesh, Khosro Khajeh

引用次数: 0

Drug repurposing for bacterial infections. 针对细菌感染的药物再利用。

3区生物学

Progress in molecular biology and translational science Pub Date : 2024-01-01 Epub Date: 2024-05-11 DOI: 10.1016/bs.pmbts.2024.03.031

Mahnoor Ilyas, Muhammad Saad Latif, Alvina Gul, Mustafeez Mujtaba Babar, Jayakumar Rajadas

{"title":"Drug repurposing for bacterial infections.","authors":"Mahnoor Ilyas, Muhammad Saad Latif, Alvina Gul, Mustafeez Mujtaba Babar, Jayakumar Rajadas","doi":"10.1016/bs.pmbts.2024.03.031","DOIUrl":"https://doi.org/10.1016/bs.pmbts.2024.03.031","url":null,"abstract":"Repurposing pharmaceuticals is a technique used to find new, alternate clinical applications for approved drug molecules. It may include altering the drug formulation, route of administration, dose or the dosage regimen. The process of repurposing medicines starts with screening libraries of previously approved drugs for the targeted disease condition. If after an the initial in silico, in vitro or in vivo experimentation, the molecule has been found to be active against a particular target, the molecule is considered as a good candidate for clinical trials. As the safety profile of such molecules is available from the previous data, significant time and resources are saved. These advantages of drug repurposing approach make it especially helpful for finding treatments for rapidly evolving conditions including bacterial infections. An ever-increasing incidence of antimicrobial resistance, owing to the mutations in bacterial genome, leads to therapeutic failure of many approved antibiotics. Repurposing the approved drug molecules for use as antibiotics can provide an effective means for the combating life-threatening bacterial diseases. A number of drugs have been considered for drug repurposing against bacterial infections. These include, but are not limited to, Auranofin, Closantel, and Toremifene that have been repurposed for various infections. In addition, the reallocation of route of administration, redefining dosage regimen and reformulation of dosage forms have also been carried out for repurposing purpose. The current chapter addresses the drug discovery and development process with relevance to repurposing against bacterial infections.","PeriodicalId":21157,"journal":{"name":"Progress in molecular biology and translational science","volume":"207 ","pages":"1-21"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141470504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0